Pharma Major Lupin

Indian pharmaceutical manufacturer Pharma Major Lupin intends to purchase the Biocom plant in Stavropol, Lupin said in a statement. The amount of the potential transaction has not been disclosed.

“The acquisition marks Lupin’s foray into the Russian pharmaceutical market which recorded RUB 765 billion in sales, placing it as one of the Top 10 pharmaceutical markets in the world in 2014,” the press release says.

Biocom had turnover of RUB 861.2 million in 2014, according to Lupin.

“We are excited about our entry into the Russian market through Biocom. Russia is an attractive market and this acquisition will also enable our expansion into neighboring markets as well as other Eastern European markets in the future,” Lupin Limited CEO Vinita Gupta commented.

01 July 2015
Stavropol region

Investor profile

Pharma Major Lupin


Company's website:

T: +91 22 6640 2222

Public company


Contact: Dr. Desh Bandhu Gupta, Founder and Chairman of the Board of Directors

Lupin Pharmaceuticals Inc is India’s fourth biggest pharmaceutical company by sales volume. Lupin specializes in the production of generic and brand drugs as well as active pharmaceutical substations. The company was established in 1968 and its products are present in more than 100 countries. Revenue totalled USD 1.8 billion in the 2013—2014 financial year, while net profit amounted to USD 299.9 million. Lupin ranks fifth among generics manufacturers in the U.S. and is the third largest pharmaceutical manufacturer in India in terms of revenue.